0001209191-20-064020.txt : 20201217
0001209191-20-064020.hdr.sgml : 20201217
20201217160108
ACCESSION NUMBER: 0001209191-20-064020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201215
FILED AS OF DATE: 20201217
DATE AS OF CHANGE: 20201217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Connell Joseph P
CENTRAL INDEX KEY: 0001723966
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38318
FILM NUMBER: 201396063
MAIL ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Odonate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001717452
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822493065
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-200-3830
MAIL ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Odonate Therapeutics, Inc
DATE OF NAME CHANGE: 20171207
FORMER COMPANY:
FORMER CONFORMED NAME: Odonate Therapeutics, LLC
DATE OF NAME CHANGE: 20170919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-15
0
0001717452
Odonate Therapeutics, Inc.
ODT
0001723966
O'Connell Joseph P
C/O ODONATE THERAPEUTICS, INC.
4747 EXECUTIVE DRIVE, SUITE 210
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Common Stock
2020-12-15
4
A
0
121
12.91
A
3000
D
Employee Stock Option (Right to Buy)
15.19
2020-12-15
4
A
0
121
0.00
A
2030-12-15
Common Stock
121
121
D
These shares were acquired on 12/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ Michael Hearne, as attorney-in-fact for Joseph O'Connell
2020-12-17